Brokerages Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $10.75

Shares of Zura Bio Limited (NASDAQ:ZURA) have received an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $10.75.

A number of brokerages have commented on ZURA. Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Chardan Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a research note on Friday, November 14th. Wall Street Zen lowered Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $6.01 on Thursday. The business’s 50-day simple moving average is $4.86 and its 200 day simple moving average is $3.49. The company has a market cap of $390.77 million, a P/E ratio of -9.25 and a beta of 0.21. Zura Bio has a one year low of $0.97 and a one year high of $6.63.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Savant Capital LLC raised its stake in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after purchasing an additional 21,249 shares in the last quarter. Scientech Research LLC acquired a new stake in Zura Bio during the third quarter valued at approximately $45,000. AQR Capital Management LLC bought a new position in Zura Bio during the 1st quarter worth approximately $72,000. Forefront Wealth Partners LLC bought a new position in Zura Bio during the 3rd quarter worth approximately $93,000. Finally, Bank of America Corp DE increased its holdings in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.